FlipTx offers an in vivo immune cell reprogramming platform that uses proprietary mRNA payloads delivered via lipid‑nanoparticle technology to convert pathogenic T cells into anti‑inflammatory, homeostatic cells at sites of inflammation. By simultaneously depleting disease‑driving T cells and expanding protective immune cells, the approach aims to restore immune balance and achieve durable resolution of autoimmune and inflammatory diseases, providing a curative alternative to chronic symptom‑management therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Autoimmune and inflammatory diseases affect hundreds of millions of people, and existing therapies often provide only symptomatic relief, carry significant side effects, and require lifelong treatment without achieving a cure.
Solution
FlipTx develops an in vivo immune cell reprogramming platform that converts pathogenic T cells into anti‑inflammatory, homeostatic cells directly at sites of inflammation. The approach uses proprietary mRNA payloads encoded to re‑educate T cells, delivered by clinically validated lipid‑nanoparticle (LNP) technology. By reducing the number of local disease‑driving cells and restoring protective immune functions, the platform aims to re‑establish immune balance and achieve durable disease resolution, moving beyond chronic symptom management toward curative outcomes.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing therapies for autoimmune and inflammatory diseases, as well as clinical research organizations seeking novel curative approaches.
Features
- Proprietary mRNA constructs that encode reprogramming factors to shift pathogenic T cells toward anti‑inflammatory phenotypes
- Clinically proven LNP delivery system enabling efficient, tissue‑targeted in vivo transfection of T cells
- Dual mechanism that both depletes local inflammatory T cells and expands protective immune cells at the disease site
- Designed for broad applicability across multiple autoimmune and inflammatory indications
- Scalable manufacturing platform leveraging established mRNA‑LNP production processes